Isonics Corporation to Exhibit at SEMICON Europa; Company to Present Next-Generation Technology at High Profile International Conference.

Business Editors/High-Tech Writers

SEMICON Europa

Booth B2.519

GOLDEN, Colo.--(BUSINESS WIRE)--April 15, 2004

Isonics Corporation (Nasdaq:ISON), a leading supplier of silicon-on-insulator (SOI) wafers for the semiconductor industry, announced today that the Company will be exhibiting its semiconductor product lines at SEMICON Europa (www.semi.org) in Munich, Germany, April 20-22, Booth B2.519.

SEMICON Europa is the largest international conference and exposition for semiconductor equipment and materials in all of Europe.

With today's push for faster, less expensive and more energy efficient semiconductor equipment and products, SOI wafers have become the fastest growing segment of the multi-billion dollar silicon wafer market. On the cutting edge of new technology for this market, including utilization of scientific advances in the field of nanotechnology, Isonics provides a wide range of product specifications and wafer sizes, specializing in those requiring a high degree of customization.

Isonics manufactures SOI wafers for micro-electro mechanical systems (MEMS) and integrated circuit (IC) applications, and isotopically pure silicon-28 epitaxial wafers with improved thermal conductivity, which allows peak chip performance at high operating temperatures and the manufacture of higher density integrated circuits resulting in increased performance and improved chip yields. The major advantages of isotopically pure silicon-28 are that it has better thermal properties than standard silicon and can be used without any changes to existing silicon semiconductor manufacturing processes.

James E. Alexander, Isonics' president and CEO remarked, "We are very excited for the opportunity to show our next-generation technology to the European marketplace as Isonics is committed to aggressively expanding its markets on a worldwide basis. The international semiconductor industry has already recognized that silicon-28 can address some of the thermal management problems in high power devices, and we expect that our improved silicon wafers will become an important part of the solution to this problem as the industry transitions to the next wave of technology. Semiconductor manufacturers have already been sampling silicon-28 epitaxial wafers, and we expect a number of publications in 2004 describing favorable technical results."

Isonics recently announced a letter of intent to acquire the wafer business and related assets of Vancouver, WA based Encompass Materials which, if completed, will permit Isonics to expand its SOI wafer operation and enter the test wafer and wafer reclaim market. Isonics plans to introduce these new capabilities to European semiconductor customers at SEMICON Europa. In addition, through advances in nanotechnology, the Company plans to pursue additional advances in silicon products and manufacturing processes.

Isonics Corporation is a world leader in isotopically engineered materials and produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. Isonics also markets and sells stable isotopes for the health care industry such as carbon-13 for diagnostic breath tests and drug design, and oxygen-18 for positron emission tomography (PET) imaging. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Additional information may be obtained at the Company's Web site at http://www.isonics.com.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB for the year ended April 30, 2003, and its quarterly report on Form 10-QSB for the nine months ended January 31, 2004, both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.